AMSBIO has launched a new range of research grade biosimilars that enable analysis of biological processes without the need to purchase expensive therapeutic-grade biologics.

  • Enables accurate modelling of the human colon and the mucosal barrier

  • Provides new insights to the relationship between human microbiome and effect on human health

  • Model to be integrated into CN Bio’s PhysioMimix™ OOC range of single- and multi-organ microphysiological systems



Metrion Biosciences appoints Nick Foster as Chief Commercial Officer and Head of Global Business Development

Appointment supports international growth within ion channel contract research and drug discovery 


Reading Scientific Services Ltd (RSSL) has enhanced its Investigative and Quality Control (QC) capabilities with the installation of a new 600 MHz Bruker AVANCE NEO Nuclear Magnetic Resonance (NMR) spectrometer at its UK laboratories. The investment not only increases the scientific consultancy’s capacity to develop tailored analytical solutions, it also paves the way for further investigations into new NMR applications for the Life Science sectors.

Cambridge, United Kingdom – Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, today announces that its genomic interpretation software is now CE marked under the In Vitro Diagnostics Directive (98/79/EC).

Increasing numbers of employees are being asked to self-isolate after being exposed to COVID, putting pressure on employers.

Employment lawyer, and Partner, Helen Farr was featured on BBC Radio 5 Live.

Click the link to listen.

SOMERSET, N.J. – July 21, 2021 — Catalent, the leading global provider of advanced delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products, today announced that it will commence the first phase of a planned $100 million expansion program at its facility in Anagni, Italy, to add biologics drug substance manufacturing capabilities, supporting the growing European market demand for biologics manufacture and supply.

20 July 2021: Future Fund: Breakthrough, announced by the Chancellor of the Exchequer at Budget 2021, opens today for applications. This UK-wide programme will deliver £375m of government funding via British Patient Capital, a commercial subsidiary of the British Business Bank.

NHS patients are set to benefit from early access to potentially life-saving new medicines, including cutting-edge gene therapies, thanks to a new Innovative Medicines Fund and £680 million of ringfenced funding, the NHS chief executive has announced today.

Cambridge, UK: 20 July 2021

One Nucleus, the non-for-profit Life Science membership group headquartered in Cambridge, exists to support growing Life Science businesses throughout their life cycle as they translate great science into better patient outcomes. This includes promoting and leveraging the world class excellence within our network and beyond, by facilitating the right connections.